Program
dapirolizumab pegol
Also written as “Dapirolizumab pegol (DZP)”, “DZP” and “CDP7657”.
Its studies are mostly in Lupus Erythematosus, Systemic, led by 2 companies.
Drug pageDapirolizumab pegol: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCBits history only | 73 open or running | phase 3since Feb 27, 2020 | Mar 12, 2010 | May 31, 2028phase 3 · NCT06617325 |
| Biogen | 10 open or running | phase 1since Sep 25, 2020 | Sep 25, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Biogen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 25, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04571424 · 33 enrolled · United States
TargetBeta
“CD40 ligand inhibitor”ChEMBL 37, by rule
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| frexalimab | Sanofi | phase 3 | 11 |
| dazodalibeprule | Amgen | phase 3 | 9 |
| tegoprubartrule | eledon-pharmaceuticals | phase 3 | 8 |
| ravagalimabrule | AbbVie | phase 2 | 4 |
| OPT101rule | op-t-llc | phase 2 | 4 |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 1 |
Studies
The one study Biogen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04571424Healthy Volunteers · United States | 1 | Completed | Apr 8, 2021 | 33 |
How it is read
Names in the registry
- “Dapirolizumab pegol (DZP)”, 2 entries
- “DZP”, 2 entries
- “CDP7657”, 2 entries
- “Dapirolizumab pegol”, 1 entry
- “BIIB133 (Dapirolizumab pegol)”, 1 entry
Codes read as this program: CDP7657.
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.